EBS Emergent Biosolutions, Inc. Com

30.20
-0.07  -0%
Previous Close 30.27
Open 30.46
Price To book 2.03
Market Cap 1.24B
Shares 40,974,000
Volume 156,796
Short Ratio 9.94
Av. Daily Volume 311,836

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease

Latest News

  1. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : May 24, 2017
  2. ETFs with exposure to Emergent BioSolutions, Inc. : May 22, 2017
  3. Emergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
  4. Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available
  5. Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore
  6. Edited Transcript of EBS earnings conference call or presentation 4-May-17 9:00pm GMT
  7. Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
  8. Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth
  9. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : May 8, 2017
  10. Emergent Biosolutions beats 1Q profit forecasts
  11. Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
  12. Emergent BioSolutions, Inc. – Value Analysis (NYSE:EBS) : April 27, 2017
  13. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US : April 26, 2017
  14. Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
  15. Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
  16. Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : March 20, 2017
  17. Emergent BioSolutions gets $100 million anthrax contract from feds
  18. Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile
  19. Local drug company stocks react to Trump's proposed cuts to NIH, FDA
  20. Blog Coverage Galapagos Announced New Phase-II Studies Led by Filgotinib Collaboration Partner Gilead Sciences